Tech Company Financing Transactions
TetraLogic Pharmaceuticals Funding Round
Pfizer Venture Investments participated in a $5 million Series C funding round for TetraLogic Pharmaceuticals. The funding round was announced by the company on 9/27/2010.
Transaction Overview
Company Name
Announced On
9/27/2010
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance clinical development of TL32711, TetraLogic's lead drug candidate for the treatment of cancer.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
343 Phoenixville Pike
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
TetraLogic Pharmaceuticals (NASDAQ: TLOG) discovers and develops novel, targeted drugs to treat cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kevin Buchi
Chief Financial Officer
Patrick Hutchison
Chief Medical Officer
Jeffrey Skolnik
Chief Scientific Officer
Stephen Condon
VP - General Counsel
Richard Sherman
VP - Operations
Tony Meehan
VP - R & D
Glenn Begley
Browse more venture capital transactions:
Prev: 9/27/2010: Harvest Automation venture capital transaction
Next: 9/27/2010: OpGen venture capital transaction
Share this article
News on VC Transactions
We report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs